Current stock page

Financial Data

KYMR Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

KYMRKymera Therapeutics, Inc.

Healthcare / Biotechnology

Absolute Strength

Above Peers

BullishEdge 7/10
$127.57+$0.40 (+0.31%)

Latest quote

  • Momentum
    87
  • Value
    43
  • Quality
    57
  • Risk resilience
    60
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$65M$34.37M$2.86M$2.76M$11.48M$22.1M$7.39M
Gross Profit$0$65M$34.37M$79.04M-$71.33M$9.39M$22.1M$7.39M
Operating Income-$147.23M-$75.61M-$84.15M-$97.9M-$92.52M-$84.56M-$74.43M-$80.76M
Net Income-$132M-$61.21M-$69.23M-$87.03M-$82.18M-$76.61M-$65.58M-$70.75M
EPS-$1.32-$0.62-$0.71-$0.98-$0.94-$0.95-$0.82-$0.88
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$77.91M-$54.07M-$88.84M-$66.75M-$27.11M-$59.88M-$79.15M-$61.78M
Capital Expenditure-$315K-$473K-$434K-$106K-$181K-$695K-$467K-$936K
Free Cash Flow-$78.23M-$54.54M-$89.27M-$66.85M-$27.29M-$60.58M-$79.62M-$62.72M
Net Cash Provided By Operating Activities-$77.91M-$54.07M-$88.84M-$66.75M-$27.11M-$59.88M-$79.15M-$61.78M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.77B$1.65B$1.67B$1.74B$1.1B$1.13B$918.31M$978.04M
Total Debt$76.6M$82.22M$80.47M$82.25M$84M$85.71M$86.33M$87.76M
Cash And Cash Equivalents$373.37M$124.48M$144.09M$357.01M$112.95M$335.82M$89.97M$120.26M
Total Liabilities$152.74M$139.85M$129.38M$163.15M$155.79M$159.59M$132.08M$142.42M
Total Stockholders Equity$1.61B$1.51B$1.54B$1.58B$946.26M$971.48M$786.23M$835.62M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio7.66.865.145.085.533.123.072.9
P/S ratio124.91———————
Debt To Equity0.050.050.050.050.090.090.110.11
Free Cash Flow Yield-2.35%-2.30%-3.09%-2.92%-4.40%-8.34%-9.96%-8.57%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio7.66.865.145.085.533.123.072.9
P/S ratio124.91———————
Return On Equity-21.65%-19.85%-20.46%-19.71%-31.19%-28.35%-30.64%-26.79%
Debt To Equity0.050.050.050.050.090.090.110.11

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-35.14x
Pb7.91x
Revenue Growth Yoy-100.00%
EPS Growth Yoy-40.43%
Gross Margin174.52%
Operating Margin-396.08%
ROE-22.39%
ROIC-23.94%
Debt To Equity0.05
FCF Yield-2.65%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$127.57
Volume808,783
RSI (14)54.88
MACD5.1
MACD signal4.84
MACD histogram0.26
ADX (14)33.3
SMA (50)$117.13
SMA (200)$99.45
ATR (14)$6.70
Historical volatility (annualized)54.72%
Volume (20-day average)991,506

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score60/100
Beta0.92
Annual volatility63.12%
Max Drawdown-27.74%
Sharpe Ratio1.33
VaR (95%, 1-day)-4.36%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

KYMR Financial Data FAQ

What is Kymera Therapeutics, Inc.'s revenue?

Kymera Therapeutics, Inc.'s revenue is one of the core financial data points for KYMR. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Kymera Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Kymera Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is KYMR's EPS?

KYMR's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Kymera Therapeutics, Inc.'s net income?

Kymera Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Kymera Therapeutics, Inc. generate?

Free cash flow shows how much cash Kymera Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Kymera Therapeutics, Inc. have?

Cash and debt help frame KYMR's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.